Cilgavimab Antibody

SKU: orb1980447

Description

Cilgavimab (AZD-1061) is a human monoclonal antibody designed to neutralize SARS-CoV-2 by binding to its spike protein. It has been investigated in clinical studies for the treatment and prevention of COVID-19, demonstrating utility in both in vitro neutralization assays and in vivo therapeutic research.

Research Area

Infectious Disease & Virology

Images & Validation

−

Key Properties

−

CAS Number	2420563-99-9
MW	148.54 kDa
Purity	95.00%
Target	SARS-CoV

Bioactivity

−

In Vivo	In a mouse model of SARS-CoV-2 infection, Cilgavimab (200 μg/ dose) treatment reduced the expression of inflammatory cytokine and chemokine genes in the lungs of the mice, reducing viral burden and lung inflammation levels. Read more...
In Vitro	Cilgavimab has strong monoclonal antibody neutralization activity and human ACE2 blocking activity with IC50 of 10-150 ng/mL. Cilgavimab can bind to trimer S2Pecto protein or monomer SRBD protein with IC50 of 0.1-10 ng/mL. Read more...

Storage & Handling

−

Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

COV22130, COV2-2130, AZD 5156, AZD1061, AZD-1061, AZD5156

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Quick Database Links

Gene Symbol

SARS-CoV

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols